AstraZeneca

AstraZeneca

Shareholders Approve CEO Soriot's £18.7mn Pay

Despite a revolt from almost 36 per cent of shareholders, AstraZeneca's CEO Soriot's £18.7mn pay has been approved. The pharma group's boss received a £1.8mn rise in pay, which was met with disapproval from a significant portion of the company's shareholders.

Impact on AstraZeneca's Reputation

This decision to increase the CEO's pay comes at a time when there is growing scrutiny on executive compensation in the corporate world. AstraZeneca will need to carefully manage the fallout from this decision to ensure that it does not negatively impact the company's reputation and relationships with shareholders.